Recombinant Human papillomavirus type 16 Protein E6(E6)

In Stock
Code CSB-EP365854HML
Size US$1726Purchase it in Cusabio online store
(only available for customers from the US)
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP365854HML could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) E6.
  • Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP365854HML could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) E6.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Description

Recombinant Human Papillomavirus (HPV) 16 Protein E6 produced in E.Coli (identified by the LC-MS/MS Analysis) contains 158 amino acids covering the full length of HPV-16. And it has its N-terminus fused with a 6xHis tag and a total molecular weight of 23.2 kDa. The purity of this HPV-16 E6 protein is greater than 90% as measured by SDS-PAGE. In stock of this protein means there is no waiting period for protein preparation. Importantly, this recombinant HPV-16 E6 protein can be used in the studies of epigenetics and neuclear signaling research area.

HPV type 16 is one of the most prevalent high-risk HPVs causally related to anogenital malignancies as well as head &neck tumors. Its encoding intracellular oncoprotein E6 is implicated in the immortalization and maligant transformation of HPV-infected cells. HPV -16 E6 exerts these functions by facilitating telomerase activity and targeting p53 tumour suppressor for rapid proteasome-mediated degradation via E6/E6AP complexes.

Purity Greater than 90% as determined by SDS-PAGE.
Target Names E6
Uniprot No. P03126
Research Area Epigenetics and Nuclear Signaling
Alternative Names E6; Protein E6
Species Human papillomavirus type 16
Source E.coli
Expression Region 1-158aa
Target Protein Sequence MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 23.2 kDa
Protein Length Full Length
Tag Info N-terminal 6xHis-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Background

Function
(From Uniprot)
Plays a major role in the induction and maintenance of cellular transformation. Acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. E6 associates with host UBE3A/E6-AP ubiquitin-protein ligase, and inactivates tumor suppressors TP53 and TP73 by targeting them to the 26S proteasome for degradation. In turn, DNA damage and chromosomal instabilities increase and lead to cell proliferation and cancer development. The complex E6/E6AP targets several other substrates to degradation via the proteasome including host DLG1 or NFX1, a repressor of human telomerase reverse transcriptase (hTERT). The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization. Other cellular targets including BAK1, Fas-associated death domain-containing protein (FADD) and procaspase 8, are degraded by E6/E6AP causing inhibition of apoptosis. E6 also inhibits immune response by interacting with host IRF3 and TYK2. These interactions prevent IRF3 transcriptional activities and inhibit TYK2-mediated JAK-STAT activation by interferon alpha resulting in inhibition of the interferon signaling pathway.
Gene References into Functions
  1. USP15 could increase the level of HPV16 E6 by inhibiting E6 degradation. PMID: 29895155
  2. Up-regulation of miR-20a by HPV16 E6 exerted growth-promoting effects by targeting PDCD6 in cervical carcinoma cells. PMID: 29710555
  3. The HPV16-E6 oncoprotein induces EMT in transgenic mice cataracts. The molecular mechanism may involve TGF-beta and Wnt/beta-catenin pathways, suggesting that the K14E6 transgenic mouse could be a useful model for the study or treatment of EMT-induced cataracts. PMID: 29888254
  4. This study provides links between the DNA damage response, the regulation of E6 human papillomavirus type 16 PDZ binding motif function, and the inhibition of p53 activity and begins to explain how virus-infected cells remain within the cell cycle, despite activation of DNA damage response pathways during productive virus infections. PMID: 29848585
  5. E6 oncogene alters host gene expression in the cervical stroma. PMID: 29073104
  6. the K14E6 versus K14E6Delta146-151 transcriptional profile provides a source of valuable data to uncover novel E6 functions in the skin. PMID: 29130045
  7. HPV16 E6 T178G mutation increases the disease risk of cervical intraepithelial neoplasia 2 and 3 PMID: 29787003
  8. the network of transcriptional interactions in HPV16-infected basal-type cervical epithelium is regulated in a concentration-dependent manner by E6/E7, via a limited number of central master-regulators. PMID: 27457222
  9. E6 association with cellular PDZ proteins promotes the nuclear localization of YAP1. PMID: 29346075
  10. Results showed that increased expression of HPV16 E6 expression level was strongly associated with malignant transformation of the cervical epithelium and the histological progression of cervical squamous cell carcinoma. PMID: 29470526
  11. human papillomavirus 16 E6, E7 genes and Long Control Region are expressed in cervical samples from Uruguayan women PMID: 29454092
  12. HPV16 E6 oncoprotein promoted the bioactivities of non-small cell lung cancer (NSCLC) cells. TLR3-Src signaling pathway might be involved in this procession by up-regulation of cytokine production. The interaction between HPV16 E6 protein and TLR3 might contribute to the poor prognosis of NSCLC. PMID: 28480962
  13. HPV16 E6-E7 promotes cancer stem-like cells phenotype in esophageal squamous cell carcinoma cells through the activation of PI3K/Akt signaling pathway PMID: 27489353
  14. Studied role of HPV16 E6 and COX-2 in invasive ductal breast cancer using qPCR and IHC, and in vitro studies. Found HPV16 E6 promoted breast cancer proliferation; Cox-2 inhibition suppressed HPV16 E6 effects on proliferation thru NF-kappaB signaling pathway. PMID: 29250535
  15. Findings indicate O-linked N-acetylglucosamine transferase (OGT) as a cellular factor involved in human papillomaviruses type 16/18 E6 and E7 expressions and cervical cancer tumorigenesis, suggesting that targeting OGT in cervical cancer may have potential therapeutic benefit. PMID: 27331873
  16. IFN-beta treatment leads to p53-indipendent apoptosis in K16 cells whereas induces senescence in K16 cells if E6 is silenced and p53 expression is restored. The levels of selected miRNAs, deregulated in K16 and K38 cells, can be modulated by IFN-beta when E6 and E7 proteins of HPV-16, but not HPV-38, are expressed. PMID: 26748726
  17. A decrease in miR-184 level by E6 oncoprotein may predict unfavorable response to cisplatin-based chemotherapy in HPV-infected non-small cell lung carcinoma patients via increasing Bcl-2 expression. PMID: 27083050
  18. Seminal studies over the last two decades have identified the transcriptional, epigenetic, and post-transcriptional roles high-risk E6 and E7 have in TERT regulation. (Review) PMID: 27863966
  19. Ablation of E6 by siRNA induces the tumor suppressor p53 and diminishes beta-defensin-3 (hBD3) in HPV-16 positive CaSki cervical cancer cells and UM-SCC-104 head and neck cancer cells. PMID: 27034006
  20. This study identifies NFX1-123 as a critical host protein partner through which 16E6 is able to subvert the immune response and in turn permit a long-lived high-risk Human papillomavirus infection. PMID: 29117186
  21. HPV E6 is capable of overriding this regulation and can promote degradation of p53 and Dlg regardless of the phosphorylation status of E6AP. PMID: 28835500
  22. Studies indicate the accuracy of HPV16 antibodies to the oncoproteins E6. PMID: 28316084
  23. Lactate and glucose production were enhanced in E6-transduced keratinocytes, likely due to raised levels of metabolic enzymes, but independent of(HIF-1alpha activity. PMID: 28857035
  24. These data highlight the importance of the carboxy-terminal motif of the E6 protein and downregulation of PAR3 in tumorigenic transformation of human cervical keratinocytes. PMID: 28440909
  25. Study presented a combined molecular dynamics/infrared spectroscopy approach to the study of ligand binding (11-residue peptide derived from the C terminus of HPV16 E6) by the PDZ1 domain of MAGI1, focusing in particular on the far-infrared region of the spectrum. PMID: 28636914
  26. HPV16 E6/E7 oncogene expression in primary human epithelial cells alters miR expression in extracellular vesicles. PMID: 28500882
  27. In three warty or basaloid SCSC HPV16-DNA and E6*I-mRNA were detected. LCM-PCR confirmed HPV16 was in p16(INK4a)-positive malignant cells. However, of three usual-type SCSC, all were HPV-negative and two expressed p53 protein but not p16(INK4a). PMID: 28376081
  28. HPV-16 E6 was confirmed to regulate microRNA miR-23b indirectly through the DNA methylation of host gene C9orf3 and thus induce c-MET and inhibit apoptosis in cervical cancer cells. PMID: 28077801
  29. Our results indicate that HPV16 E6/E7 indirectly upregulated the expression of VEGF by inhibition of liver kinase B1 expression and upregulation of hypoxia-inducible factor 2alpha expression,thus propose a human papillomavirus-liver kinase B1-hypoxia-inducible factor 2A-vascular endothelial growth factor axis for the tumorigenesis of lung cancer PMID: 28720067
  30. HPV E6/E7 increased expression of DROSHA and DICER mRNA and protein in cervical carcinoma cells. PMID: 28448850
  31. Data show that p63 transcription factors modulate cell migration via Src-focal adhesion kinase (FAK) signaling in foreskin keratinocytes (HFK) expressing human papilloma virus (HPV)16 E6/E7 genes. PMID: 26001294
  32. Overall, this study supports the model that perturbation of cellular miR expression by human papillomavirus type 16 E6/E7 importantly contributes to the rewiring of cellular regulatory circuits that contributes to oncogenic transformation. PMID: 28049151
  33. Thus, Brd4 activates human papillomavirus 16 transcription at this integration site, and strong selection for E6/E7 expression can drive the formation of a super-enhancer-like element to promote oncogenesis. PMID: 27624132
  34. Collectively, these results indicate that human papillomavirus 16 E6 induces upregulation of APOBEC3B through increased levels of TEADs, highlighting the importance of the TEAD-APOBEC3B axis in carcinogenesis. PMID: 28077648
  35. A transcriptomic landscape of human papillomavirus 16 E6-regulated gene expression and splicing events in cervical cancer patients has been presented. PMID: 27859058
  36. The ubiquitylation of beta-catenin by E6AP was dependent on its E3 ubiquitin ligase activity, but it was proteasome-independent and did not require HPV16-E6. PMID: 27902311
  37. nucleotide changes in E6 occur significantly more often in the mixed form of viral DNA and in low-grade squamous intraepithelial lesions; and the variants without additional mutations may promote integration of HPV16 genome. PMID: 27801430
  38. We also found VPA suppressed oncogene E6 in a Notch-independent manner, and induced significant apoptosis in E6-overexpressing HPV positive CaSki cells. PMID: 27176495
  39. Data show that alpha-linolenic acid (ALA) decreased the expression of VEGF and COX2 proteins, and reduced the expression of Human papillomavirus type 16/18 onco-proteins E6 and E7, resulting into restoration of expression of tumor suppressor proteins, p53 and Rb in cervical cancer cell lines. PMID: 26440049
  40. Expression changes of E6 and E7 significantly promoted the protein expression of HIF-1alpha, the expression of both protein and mRNA of GLUT1, but had no effect on the expression of HIF-1alpha mRNA in lung cancer cells. PMID: 26508030
  41. our results suggest that ERK1/2 signaling pathway is involved in HPV-16 E6 but not E7 oncoprotein-induced HIF-1a, VEGF, and IL-8 expression in NSCLC cells, leading to the enhanced angiogenesis in vitro. PMID: 26931433
  42. Our data suggest that the use of HPV 16 spliced transcripts may help to predict for poorer outcomes in patients with HPV positive oropharyngeal cancer PMID: 26575468
  43. Within the limitations of this study, the immunoexpression of HPV 16/18 E6 and E7 oncoproteins may have prognostic value regarding cervical squamous intraepithelial lesions persistence in HIV-positive women. PMID: 26909984
  44. HPV16 E6/E7 Oncoproteins Alter the In Vitro Growth of CD44+NGFR+ Human Tonsillar Epithelial Cells. PMID: 26527383
  45. Human papillomavirus type 16 E6 protein, a major etiological molecule of cervical cancer, maintains high YAP protein levels in cervical cancer cells by preventing proteasome-dependent YAP degradation to drive cervical cancer cell proliferation. PMID: 26417066
  46. E6 and E7 have roles in methylation of tumor suppressor genes and inducing phenotype transformation of human cervical carcinoma cells PMID: 26329329
  47. Here we demonstrate that E7, and to a lesser extend E6, strongly reduce NFkappaB activation in response to the inflammatory mediator imiquimod. Moreover, we establish that undifferentiated keratinocytes do not express the putative receptor for imiquimod, TLR7 PMID: 26268216
  48. The data indicate for the first time that increased cytoplasmic human papillomavirus type 16 E6 levels associated with malignant progression alter Cx43 trafficking and recycling to the membrane and the E6/human Dlg interaction may be involved. PMID: 26445057
  49. High-risk HPV-type lesions might inhibit the chemokine CCL20 on Langerhans cells through E6 and E7 to escape the immune response. PMID: 26400278
  50. E6 protein functioning as a host miRna modulator and play a role of HPV induced carcinogenesis in patient diagnosed with cervical cancer. PMID: 26384051

Show More

Hide All

Subcellular Location Host cytoplasm, Host nucleus
Protein Families Papillomaviridae E6 protein family
Database Links

KEGG: vg:1489078

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1